JP2019526561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526561A5 JP2019526561A5 JP2019510788A JP2019510788A JP2019526561A5 JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5 JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- alkylene
- composition
- alkyl
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/096472 | 2016-08-24 | ||
| CN2016096472 | 2016-08-24 | ||
| PCT/CN2017/098575 WO2018036498A1 (en) | 2016-08-24 | 2017-08-23 | Entacapone-related compounds to treat macular degeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021013670A Division JP7116202B2 (ja) | 2016-08-24 | 2021-01-29 | 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526561A JP2019526561A (ja) | 2019-09-19 |
| JP2019526561A5 true JP2019526561A5 (ja�@�@) | 2020-07-16 |
| JP6898429B2 JP6898429B2 (ja) | 2021-07-07 |
Family
ID=61245496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510788A Active JP6898429B2 (ja) | 2016-08-24 | 2017-08-23 | 黄斑変性症を治療するためのエンタカポン関連化合物 |
| JP2021013670A Active JP7116202B2 (ja) | 2016-08-24 | 2021-01-29 | 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021013670A Active JP7116202B2 (ja) | 2016-08-24 | 2021-01-29 | 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10980766B2 (ja�@�@) |
| EP (1) | EP3503883B1 (ja�@�@) |
| JP (2) | JP6898429B2 (ja�@�@) |
| CN (1) | CN109689042B (ja�@�@) |
| AU (1) | AU2017317129B2 (ja�@�@) |
| CA (1) | CA3034547C (ja�@�@) |
| WO (1) | WO2018036498A1 (ja�@�@) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532976B2 (en) * | 2015-06-23 | 2020-01-14 | National Institute Of Biological Sciences, Beijing | FTO inhibitors |
| WO2018036498A1 (en) * | 2016-08-24 | 2018-03-01 | National Institute Of Biological Sciences, Beijing | Entacapone-related compounds to treat macular degeneration |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| CA3216828A1 (en) * | 2021-04-15 | 2022-10-20 | Brown University | Nitrophenyl-acrylamides and uses thereof |
| CA3263420A1 (en) * | 2022-07-29 | 2024-02-01 | Rpxds Co., Ltd | FTO INHIBITORS |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025162358A1 (en) * | 2024-01-30 | 2025-08-07 | Rpxds Co., Ltd | Fto inhibitors of bicyclic structures |
| WO2025162373A1 (en) * | 2024-01-30 | 2025-08-07 | National Institute Of Biological Sciences, Beijing | Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI864875A0 (fi) | 1986-11-28 | 1986-11-28 | Orion Yhtymae Oy | Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa. |
| US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TW200817315A (en) | 2006-06-16 | 2008-04-16 | Sanol Arznei Schwarz Gmbh | Entacapone-derivatives |
| EP1946756A1 (en) * | 2007-01-17 | 2008-07-23 | Revotar Biopharmaceuticals AG | Use of entacapone in cosmetic, dermatological and pharmaceutical compositions |
| EP1978014A1 (en) | 2007-04-02 | 2008-10-08 | Esteve Quimica, S.A. | Process for the preparation of entacapone and intermediates thereof |
| US9827210B2 (en) * | 2007-06-29 | 2017-11-28 | Phovitreal Pty Ltd | Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration |
| EP2273988B1 (en) * | 2008-04-18 | 2015-09-09 | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona | L-dopa for treating age-related macular degeneration |
| US20110190356A1 (en) * | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| KR20130050939A (ko) * | 2010-04-12 | 2013-05-16 | 가부시키가이샤 아루떼꾸 우에노 | 망막 질환의 치료 방법 및 이를 위한 안과용 조성물 |
| WO2012142039A1 (en) * | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| JP2016504270A (ja) * | 2012-10-17 | 2016-02-12 | ザ ユニバーシティ オブ ブリストル | 眼血管形成（ｏｃｕｌａｒｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物 |
| CN103845317B (zh) | 2012-11-28 | 2018-05-08 | 北京生命科学研究所 | 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用 |
| US20160317474A1 (en) | 2013-12-18 | 2016-11-03 | Emory University | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects |
| JP6858712B2 (ja) * | 2015-01-30 | 2021-04-14 | リーバー インスティテュート フォー ブレイン ディベロップメントＬｉｅｂｅｒ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｒａｉｎ Ｄｅｖｅｌｏｐｍｅｎｔ | Ｃｏｍｔ阻害方法及び組成物 |
| WO2016123577A1 (en) * | 2015-01-30 | 2016-08-04 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| EP3303283B1 (en) | 2015-06-23 | 2021-04-21 | National Institute Of Biological Sciences, Beijing | Fto inhibitors |
| WO2018036498A1 (en) * | 2016-08-24 | 2018-03-01 | National Institute Of Biological Sciences, Beijing | Entacapone-related compounds to treat macular degeneration |
-
2017
- 2017-08-23 WO PCT/CN2017/098575 patent/WO2018036498A1/en not_active Ceased
- 2017-08-23 JP JP2019510788A patent/JP6898429B2/ja active Active
- 2017-08-23 CA CA3034547A patent/CA3034547C/en active Active
- 2017-08-23 CN CN201780052192.2A patent/CN109689042B/zh active Active
- 2017-08-23 AU AU2017317129A patent/AU2017317129B2/en active Active
- 2017-08-23 EP EP17842920.5A patent/EP3503883B1/en active Active
-
2019
- 2019-02-22 US US16/283,117 patent/US10980766B2/en active Active
-
2021
- 2021-01-29 JP JP2021013670A patent/JP7116202B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526561A5 (ja�@�@) | ||
| Crash-2 Collaborators | The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial | |
| Szaliński et al. | Fusarium keratitis—review of current treatment possibilities | |
| JP2018521092A5 (ja�@�@) | ||
| Alkeswani et al. | Treatment of tinea capitis | |
| Roy et al. | The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials | |
| JP2018523689A5 (ja�@�@) | ||
| JP2011528713A5 (ja�@�@) | ||
| JP2019515909A5 (ja�@�@) | ||
| JP2019515908A5 (ja�@�@) | ||
| CN109952304A (zh) | 一类抑制并降解cdk的化合物 | |
| JP2007520452A5 (ja�@�@) | ||
| JP2020523356A5 (ja�@�@) | ||
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| Borgia et al. | Prophylaxis of ocular infection in the setting of intraocular surgery: implications for clinical practice and risk management | |
| ES2405323T3 (es) | Tratamiento de melanoma | |
| Maccari et al. | Can allostery be a key strategy for targeting PTP1B in drug discovery? A lesson from trodusquemine | |
| JP2020510045A5 (ja�@�@) | ||
| Zhang et al. | Noncovalent bile acid oligomers as facial amphiphilic antimicrobials | |
| JP2008540528A5 (ja�@�@) | ||
| JP2014148552A5 (ja�@�@) | ||
| CA2608163A1 (en) | Hydralazine compositions and methods | |
| JP2021502379A5 (ja�@�@) | ||
| JP2019501957A5 (ja�@�@) | ||
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы |